Sanifit raises $41M for late-stage R&D program

Forbion has joined a syndicate backing a $41 million round for Spain's Sanifit, which is plotting a Phase IIb study of its lead drug SNF472, which is designed to treat cardiovascular disease related to calcification in patients with end-stage renal disease. That should be enough money to get the company through late stage development for calciphylaxis. The biotech also announced that it had named longtime GSK vet Russell Greig as chairman of the board. The round was led by Ysios Capital and included Lundbeckfond Ventures, Gilde Healthcare, Edmond de Rothschild Investment Partners, "la Caixa" and Baxter Healthcare. Release

Suggested Articles

Reata’s bardoxolone improved kidney function in a phase 3 trial of patients with a rare form of chronic kidney disease.

The suit alleges the FDA imposed the hold “without notice or explanation” and has since “rebuffed” Regenxbio’s repeated requests for an explanation.

Bolt Biotherapeutics presented positive results from animal trials of its lead drug, a tumor-targeting antibody connected to an immune stimulator.